SCHEMBL30765998

SCHEMBL30765998

C[C@@H](Nc1cnc(N2CCCCC2)n(CC(=O)OC(C)(C)C)c1=O)c1nc(-c2ccccc2)co1

nearest known ligand 0.35

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
TSHR P16473 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CKS1B P61024 4/20 0.35
SKP1 P63208 4/20 0.35
SKP2 Q13309 4/20 0.35
AKT1 P31749 1/20 0.34
AKT2 P31751 1/20 0.34
AKT3 Q9Y243 1/20 0.34
DPP4 P27487 1/20 0.33
PHGDH O43175 1/20 0.33
P2RY12 Q9H244 4/20 0.32
PIK3CA P42336 1/20 0.32
F2 P00734 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765445 0.90 AKT1 (0.37) ALDH1A1KDM4ELMNATSHRNPSR1
SCHEMBL31558527 0.88 AKT1 (0.36) ALDH1A1KDM4ELMNATSHRNPSR1
SCHEMBL30765621 0.87 GAA (0.42) ALDH1A1KDM4ELMNATSHRNPSR1
SCHEMBL30765528 0.84 ALDH1A1 (0.36) ALDH1A1KDM4ELMNATSHRNPSR1
SCHEMBL30765475 0.82 ALDH1A1 (0.36) ALDH1A1KDM4ELMNATSHRNPSR1
SCHEMBL30766047 0.80 ALDH1A1 (0.35) ALDH1A1KDM4ELMNACKS1BSKP1
SCHEMBL30766059 0.80 ALDH1A1 (0.33) ALDH1A1KDM4ELMNATSHRNPSR1
SCHEMBL30765435 0.78 F2 (0.36) TSHRAKT1AKT2AKT3F2
SCHEMBL30766002 0.78 USP2 (0.37) ALDH1A1KDM4ELMNANPSR1PIK3CA
SCHEMBL30766001 0.73 AKT1 (0.36) ALDH1A1KDM4ELMNATSHRAKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed